

This article was downloaded by: [Malmo Hogskola]

On: 18 December 2011, At: 23:05

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/ganp20>

### Indoloquinazoline alkaloids from *Euodia rutaecarpa* and their cytotoxic activities

Xin Huang<sup>a</sup>, You-Bo Zhang<sup>a</sup> & Xiu-Wei Yang<sup>a</sup>

<sup>a</sup> State Key Laboratory of Natural and Biomimetic Drugs (Peking University), Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China

Available online: 10 Oct 2011

To cite this article: Xin Huang, You-Bo Zhang & Xiu-Wei Yang (2011): Indoloquinazoline alkaloids from *Euodia rutaecarpa* and their cytotoxic activities, *Journal of Asian Natural Products Research*, 13:11, 977-983

To link to this article: <http://dx.doi.org/10.1080/10286020.2011.602015>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Indoloquinazoline alkaloids from *Euodia rutaecarpa* and their cytotoxic activities

Xin Huang, You-Bo Zhang and Xiu-Wei Yang\*

State Key Laboratory of Natural and Biomimetic Drugs (Peking University), Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

(Received 1 May 2011; final version received 28 June 2011)

Nine indoloquinazoline alkaloids (**1–9**) were isolated from the dried and nearly ripe fruits of *Euodia rutaecarpa* (Juss.) Benth. (Euodiae Fructus), along with limonin and  $\beta$ -sitosterol. Their structures were elucidated on the basis of their spectroscopic data. Among them, compounds **1** and **2** were new compounds and characterized as (7*R*,8*S*)-7-hydroxy-8-methoxy-rutaecarpine and (7*R*,8*S*)-7-hydroxy-8-ethoxy-rutaecarpine, respectively, and 1-hydroxy-rutaecarpine (**3**) and (7*R*,8*S*)-7,8-dihydroxy-rutaecarpine (**4**) were isolated from Euodiae Fructus for the first time. The nine indoloquinazoline alkaloids were evaluated for their cytotoxic activities against human promyelocytic leukemia HL-60 cells and human gastric carcinoma N-87 cells.

**Keywords:** *Euodia rutaecarpa*; indoloquinazoline alkaloids; (7*R*,8*S*)-7-hydroxy-8-methoxy-rutaecarpine; (7*R*,8*S*)-7-hydroxy-8-ethoxy-rutaecarpine; human promyelocytic leukemia HL-60 cell; human gastric carcinoma N-87 cells

### 1. Introduction

The dried and nearly ripe fruits of *Euodia rutaecarpa* (Juss.) Benth. (Euodiae Fructus), a traditional Chinese drug ‘Wu-Zhu-Yu’, have been used for the treatment of headache accompanied by retching and cold limbs, abdominal colic, weakness and edema of the legs, dysmenorrhea, epigastric distension and pain with vomiting and acid regurgitation, diarrhea occurring before dawn daily, and hyperbaropathy [1]. In searching for potential anticancer drugs from natural products, indoloquinazoline alkaloids such as evodiamine, which are one of the main chemical constituents in Euodiae Fructus [2,3], exhibited significant cytotoxic activities against murine colon cancer cell line 26-L5 [4,5] and human prostate cancer cell lines DU145 and PC3

[6]. As part of our systematic search for bioactive constituents from Euodiae Fructus [3,7–11], we herein report the isolation and structural elucidation of two new alkaloids named (7*R*,8*S*)-7-hydroxy-8-methoxy-rutaecarpine (**1**) and (7*R*,8*S*)-7-hydroxy-8-ethoxy-rutaecarpine (**2**), and 1-hydroxy-rutaecarpine (**3**) and (7*R*,8*S*)-7,8-dihydroxy-rutaecarpine (**4**) isolated from Euodiae Fructus for the first time, as well as their potential cytotoxicities against human promyelocytic leukemia HL-60 cells and human gastric carcinoma N-87 cells.

### 2. Results and discussion

An ethanolic extract of Euodiae Fructus was partitioned with cyclohexane (CHA), ethyl acetate (EtOAc) and normal butanol (BuOH), and the CHA extract was

\*Corresponding author. Email: xwyang@bjmu.edu.cn

separated by silica gel column chromatography (CC) and preparative high-performance liquid chromatography (HPLC) to yield compounds **1–11**. The structures of the known compounds were identified as 1-hydroxy-rutaecarpine (**3**) [12,13], (7*R*,8*S*)-7,8-dihydroxy-rutaecarpine (**4**) [14], rutaecarpine (**5**) [15], evodiamine (**6**) [15], wuchuyamide-I (**7**) [9], 7 $\beta$ -hydroxy-rutaecarpine (**8**) [16,17], dehydroevodiamine (**9**) [15] (Figure 1), limonin [10], and  $\beta$ -sitosterol by comparison of their NMR, MS, and physical data with those described in the literature. Compounds **3** and **4** were isolated and identified for the first time from *Euodiae Fructus*.

Compound **1** was isolated as a white amorphous powder with  $[\alpha]_{20}^D -89.7$  ( $c = 0.35$ , MeOH), and assigned the molecular formula  $C_{19}H_{15}N_3O_3$  on the basis of a quasi-molecular ion peak at  $m/z$  334.1184  $[M + H]^+$  in the HR-ESI-MS. The IR spectrum displayed characteristic absorption for N–H and OH ( $3345\text{ cm}^{-1}$ ), carbonyl group ( $1641\text{ cm}^{-1}$ ) and aromatic rings ( $1618$ ,  $1598$ , and  $1502\text{ cm}^{-1}$ ). The UV spectrum showed absorption maxima at 234, 240, 330, 345, and 362 nm due to an indole chromophore, which was characteristic diagnostics of unsubstituted moiety in

the aromatic ring of indole ring [18] and quite similar to that of **5** (rutaecarpine), suggesting that they had the same skeleton and **1** was also an indoloquinazoline alkaloid. Fourteen proton signals, including eight aromatic singlets ( $\delta_H$  7.14–8.20), one N–H proton signal [ $\delta_H$  12.21 (1H, s)], two methine proton signals [ $\delta_H$  4.89 (1H, d,  $J = 2.0$  Hz), 6.62 (1H, d,  $J = 2.0$  Hz)], and one characteristic *O*-methyl group proton signal [ $\delta_H$  3.33 (3H, s)], were observed in the  $^1\text{H}$  NMR spectrum (Table 1), in which the signals at  $\delta_H$  7.82 (1H, br d,  $J = 8.0$  Hz, H-1), 7.86 (1H, br t,  $J = 8.0$  Hz, H-2), 7.55 (1H, br t,  $J = 8.0$  Hz, H-3), and 8.19 (1H, br d,  $J = 8.0$  Hz, H-4) formed the first aromatic spin system; the signals at  $\delta_H$  7.72 (1H, br d,  $J = 8.0$  Hz, H-9), 7.16 (1H, br t,  $J = 8.0$  Hz, H-10), 7.29 (1H, br t,  $J = 8.0$  Hz, H-11), and 7.53 (1H, br d,  $J = 8.0$  Hz, H-12) made up the second aromatic spin system. Ten carbon signals bearing protons were easily determined by the HSQC experiment, which established one-bond correlation. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra displayed signals for two spin systems with 1,2-disubstituted aromatic rings, one N–H, and one amide carbonyl function ( $\delta_C$  160.5) (Table 2). Considering the structure of alkaloids isolated from




Figure 1. Structures of compounds **1–9**.

Table 1.  $^1\text{H}$  NMR spectral data of compounds **1**, **2**, and **4** (DMSO- $d_6$ , 400 MHz).

| No. H            | <b>1</b>             | <b>2</b>                 | <b>4</b>             |
|------------------|----------------------|--------------------------|----------------------|
| 1                | 7.82, 1H, br d (8.0) | 7.79, 1H, br d (8.0)     | 7.72, 1H, br d (8.0) |
| 2                | 7.86, 1H, br d (8.0) | 7.87, 1H, br d (8.0)     | 7.85, 1H, br d (8.0) |
| 3                | 7.55, 1H, br t (8.0) | 7.55, 1H, br t (8.0)     | 7.52, 1H, br t (8.0) |
| 4                | 8.19, 1H, br d (8.0) | 8.20, 1H, br d (8.0)     | 8.20, 1H, br d (8.0) |
| 7                | 6.62, 1H, d (2.0)    | 6.62, 1H, d (2.0)        | 6.51, 1H, d (2.0)    |
| 8                | 4.89, 1H, d (2.0)    | 4.97, 1H, d (2.0)        | 5.03, 1H, d (2.0)    |
| 9                | 7.72, 1H, br d (8.0) | 7.73, 1H, br d (8.0)     | 7.71, 1H, br d (8.0) |
| 10               | 7.16, 1H, br d (8.0) | 7.15, 1H, br d (8.0)     | 7.12, 1H, br d (8.0) |
| 11               | 7.29, 1H, br d (8.0) | 7.29, 1H, br d (8.0)     | 7.27, 1H, br d (8.0) |
| 12               | 7.53, 1H, br d (8.0) | 7.53, 1H, br d (8.0)     | 7.52, 1H, br d (8.0) |
| N–H              | 12.21, 1H, br s      | 12.18, 1H, br s          | 12.03, 1H, br s      |
| OH               | –                    | –                        | –                    |
| OCH <sub>3</sub> | 3.33, 3H, s          | –                        | –                    |
| 1' <sub>eq</sub> | –                    | 3.72, 1H, qd, (6.8, 9.2) | –                    |
| 1' <sub>ax</sub> | –                    | 3.51, 1H, qd, (6.8, 9.2) | –                    |
| 2'               | –                    | 1.05, 3H, t (6.8)        | –                    |

Note: All the signals were assigned by 1D and 2D NMR spectra;  $\delta$  in ppm and  $J$  (parentheses) in Hz.

Euodiae Fructus, all the spectral data showed that the structure of **1** was an indoloquinazoline alkaloid. Further analysis of the HMBC correlation between the aromatic proton at  $\delta_{\text{H}}$  8.19 and an amide

Table 2.  $^{13}\text{C}$  NMR spectral data of compounds **1**, **2**, and **4** (DMSO- $d_6$ , 100 MHz).

| No. C            | <b>1</b> | <b>2</b> | <b>4</b> |
|------------------|----------|----------|----------|
| 1                | 126.7    | 127.2    | 127.0    |
| 2                | 135.0    | 135.5    | 135.2    |
| 3                | 126.7    | 126.9    | 126.8    |
| 4                | 126.7    | 127.7    | 127.1    |
| 4a               | 120.8    | 121.0    | 121.2    |
| 5                | 160.5    | 161.1    | 161.2    |
| 7                | 76.1     | 77.0     | 79.2     |
| 8                | 71.4     | 70.1     | 63.1     |
| 8a               | 114.2    | 115.4    | 117.6    |
| 8b               | 126.5    | 126.9    | 125.8    |
| 9                | 120.5    | 120.3    | 120.3    |
| 10               | 119.9    | 120.1    | 119.9    |
| 11               | 124.7    | 125.1    | 124.8    |
| 12               | 112.7    | 113.2    | 112.9    |
| 12a              | 138.3    | 138.8    | 138.8    |
| 13a              | 126.7    | 127.2    | 126.8    |
| 13b              | 143.3    | 143.9    | 144.0    |
| 14a              | 147.1    | 147.6    | 147.5    |
| OCH <sub>3</sub> | 55.9     | –        | –        |
| 1'               | –        | 64.2     | –        |
| 2'               | –        | 15.7     | –        |

Note: All the signals were assigned by 1D and 2D NMR spectra.

carbonyl carbon at  $\delta_{\text{C}}$  160.5 suggested that the quinazoline-type substructure included the first aromatic spin system. The signals at  $\delta_{\text{H}}$  6.62 (1H, d,  $J = 2.0$  Hz) and 4.89 (1H, d,  $J = 2.0$  Hz) formed the third spin system, which were assigned to two oxygenated methine proton signals and correlated with two carbons ( $\delta_{\text{C}}$  76.1 and 71.4) in the HSQC spectrum. In the HMBC experiment (Figure 2), the proton signal at  $\delta_{\text{H}}$  6.62 correlated with carbon signals at  $\delta_{\text{C}}$  160.5 (C-5), 143.3 (C-13b), and 114.2 (C-8a), and the proton at  $\delta_{\text{H}}$  4.89 correlated with carbon signals at  $\delta_{\text{C}}$  114.2 (C-8a) and 126.5 (C-8b), suggesting that the proton signal at  $\delta_{\text{H}}$  6.62 and 4.89 were assigned to H-7 and H-8, respectively. Therefore, carbon signals at  $\delta_{\text{C}}$  76.1 and 71.4 were assigned to C-7 and C-8, respectively. The location of the methoxyl group at C-8 was deduced on the basis of HMBC correlation from the methoxyl at  $\delta_{\text{H}}$  3.33 (3H, s) to the carbon at  $\delta_{\text{C}}$  71.4. In addition, the coupling constant between H-7 and H-8 was relatively small (2 Hz). Finally, the orientations of the H-7 and H-8 protons were studied by 2D NMR experiments, which were in agreement with those of (7*R*,8*S*)-7,8-dihydroxy-rutaecarpine (**4**) [14]. From the results mentioned above, the structure




Figure 2. Key HMBC correlations of compounds **1** and **2**.

of **1** was elucidated as (7*R*,8*S*)-7-hydroxy-8-methoxy-rutaecarpine. As far as we know, this compound has not been reported previously.

Compound **2** was isolated as a white amorphous powder with  $[\alpha]_{20}^D - 52.8$  ( $c = 0.14$ , MeOH). Its molecular formula was defined as  $C_{20}H_{17}N_3O_3$  by the data of HR-ESI-MS at  $m/z$  348.1342  $[M + H]^+$ . The UV and IR spectra were very similar to those of **1**, suggesting that **2** also had a similar indoloquinazoline structure. The  $^1H$  and  $^{13}C$  NMR spectra were all almost the same as those of **1**, from which **2** differed only in the replacement of a methoxyl group by the signals of ethoxyl group [ $\delta_H$  3.72 (1H, qd,  $J = 6.8, 9.2$  Hz,  $H_{a-1'}$ ), 3.51 (1H, qd,  $J = 6.8, 9.2$  Hz,  $H_{b-1'}$ ), 1.05 (3H, t,  $J = 6.8$  Hz,  $H-2'$ );  $\delta_C$  64.2 (C-1'), 15.7 (C-2')]. The location of the ethoxyl group at C-8 was further deduced on the basis of HMBC correlation from the protons at  $\delta_H$  3.72 and 3.51 to the carbon at  $\delta_C$  70.1. The detailed assignment of  $^1H$  and  $^{13}C$  NMR spectral data of **2** (Tables 1 and 2) was based on HSQC and HMBC spectra. On the basis of the above data and comparison of  $^1H$  and  $^{13}C$  NMR spectral data (Tables 1 and 2) with those of **1**, the structure of **2** was concluded to be (7*R*,8*S*)-7-hydroxy-8-ethoxyl-rutaecarpine.

Compound **9** is a known alkaloid, its chemical structure is a rare special inner salt, and the  $R_f$  value was 0.39 on TLC plate

( $CHCl_3$ :MeOH:CH<sub>3</sub>COOH = 6:1:0.05). To further confirm the structure, 2 mg of the compound was dissolved in 400  $\mu$ l of MeOH containing 100  $\mu$ l of HCl to gain its hydrochloride salt structure (**9A**). Compound **9A** could not be spread by MeOH on TLC plate, and had no absorption at 365 nm which was different compared with compound **9** having yellow fluorescence at the same wavelength. The EIMS of **9A** gave a  $[M]^+$  peak at the  $m/z$  301, the same as compound **9**. The results mentioned above certified that the hydrogen on nitrogen atom ( $N_1$ ) in the indole nucleus of dehydroevodiamine has strong acidity and could release  $H^+$ .

The nine indoloquinazoline alkaloids isolated were evaluated for their cytotoxic activities against human cancer cell lines HL-60 and N-87 by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method [19]. These alkaloids all showed cytotoxic activities against the two cancer cell lines (Table 3). Compound **6** (evodiamine) showed significant cytotoxic activities against both HL-60 with  $IC_{50}$  of 5.88  $\mu$ M and N-87 with  $IC_{50}$  of 7.30  $\mu$ M. Compound **5** (rutaecarpine) exhibited selective activity against N-87 with  $IC_{50}$  of 8.41  $\mu$ M. In comparison with  $IC_{50}$  values (19.8  $\mu$ M) of **5** against HL-60, the cytotoxic activity was enhanced markedly when the 1-H of **5** was replaced by a hydroxyl group such as **3** (1-hydroxy-rutaecarpine) with  $IC_{50}$  of 10.1  $\mu$ M. Inter-

Table 3. Cytotoxicity of compounds **1**–**9** against two human cancer cell lines.

| Compound         | IC <sub>50</sub> values (μM) |      |
|------------------|------------------------------|------|
|                  | HL60                         | N-87 |
| <b>1</b>         | 7.82                         | 22.3 |
| <b>2</b>         | 8.31                         | 27.9 |
| <b>3</b>         | 10.1                         | 8.38 |
| <b>4</b>         | 13.7                         | 14.1 |
| <b>5</b>         | 19.8                         | 8.41 |
| <b>6</b>         | 5.88                         | 7.30 |
| <b>7</b>         | 15.1                         | 20.1 |
| <b>8</b>         | 10.1                         | 23.2 |
| <b>9</b>         | 21.7                         | 13.8 |
| VCR <sup>a</sup> | 0.11                         | 3.62 |

<sup>a</sup> VCR was used as a positive compound.

estingly, compounds **1**, **2**, **4**, and **8**, which only differ from **5** by the replacement groups at C-7 and C-8, exhibited more activities than **5** against HL-60 (IC<sub>50</sub> values: **5** < **4** ≤ **8** < **1** ≤ **2**) but showed less activities against N-87 (IC<sub>50</sub> values: **5** > **4** > **8** ≥ **1** ≥ **2**). Although the structure–activity relationship between **5** and its analogs was not conclusively demonstrated only by these data, it is likely that the C-7 and C-8 of **5** would be an important site in a selective activity against two human carcinoma cell lines mentioned above.

### 3. Experimental

#### 3.1 General experimental procedures

Optical rotation was measured on an Autopol III polarimeter (Rudolph Research Analytical, Flanders, NJ, USA) with MeOH as solvent. IR spectra were recorded on a Thermo Nicolet Nexus-470 FT-IR spectrometer as KBr disks. UV spectra were acquired on a Varian Cary 300 UV–Vis spectrophotometer in MeOH solution. Mass spectra were recorded on a Finnigan TRACE 2000 mass spectrometer (for EI-MS) and a Bruker DALTONICS APEX IV Fourier transform ICR high-resolution mass spectrometer (7.0 T, for HR-ESI-MS). 1D and 2D NMR spectra were run on a Bruker AV 400 spectrometer (400 MHz for <sup>1</sup>H NMR and 100 MHz for <sup>13</sup>C NMR)

with TMS as an internal standard. A semi-preparative reversed-phase HPLC was carried out using a HPLC system including a LC P600 pump, a UV600 UV–Vis detector, a LabTech Chrom software (LabTech Co., Beijing, China), and a Phenomenex PRODIGY ODS column (250 mm × 21.2 mm i.d., 10 μm, Phenomenex, Inc., Torrance, CA, USA) equipped with a C<sub>18</sub> guard column (8 mm × 4 mm i.d., 5 μm; Dikma, Beijing, China) cartridge system. Open CC separation was carried out using silica gel (200–300 mesh; Qingdao Marine Chemical Co., Qingdao, China). TLC was conducted on silica gel GF<sub>254</sub> plates (Merck, Darmstadt, Germany).

#### 3.2 Plant material

The dried and nearly ripe fruits of *E. rutaecarpa* (Juss.) Benth. were obtained in Xiangtan City, Hunan Province, China and authenticated by Prof. Xiu-Wei Yang, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, China. The voucher specimen (19990901) was deposited in the Herbarium of School of Pharmaceutical Sciences, Peking University (Beijing, China).

#### 3.3 Extraction and isolation

Powdered fruits of *E. rutaecarpa* (Juss.) Benth. (21 kg) were refluxed with 70% EtOH for seven times to afford an ethanolic extract. The extract was then suspended in water and partitioned with CHA, EtOAc, and BuOH to afford the corresponding extracts, 406.5 g (yield 1.93%), 532 g (2.53%), and 965 g (4.59%). The CHA extract (380 g) was subjected to silica gel CC, eluting with a gradient solvent system of CHA–CHCl<sub>3</sub> (100:0 → 0:100) to yield four fractions. Fraction 2 (43 g) was further subjected to silica gel CC, eluting with a solvent system of CHA–EtOAc (4:1) to give compounds **5** (3.3 g), **6** (120 mg), and **10** (1.2 g), and a subfraction (110 mg). The

subfraction was separated by semi-preparative reversed-phase HPLC using MeOH–H<sub>2</sub>O (65:35) as a mobile phase to yield compounds **3** (12 mg) and **7** (11 mg). Fraction 3 (54.5 g) was purified by semi-preparative reversed-phase HPLC using MeOH–H<sub>2</sub>O (60:40) as a mobile phase to afford compounds **8** (20 mg), **4** (6.8 mg), **1** (6.3 mg), and **2** (5.5 mg), and a subfraction (33.4 g). Fraction 4 was subjected to silica gel CC, eluting with a gradient solvent system of CHCl<sub>3</sub>–MeOH (10:1 → 1:1) to give compounds **9** (1.6 g) and **11** (330 mg).

### 3.3.1 (7R,8S)-7-Hydroxy-8-methoxy-rutaecarpine (**1**)

A white amorphous powder;  $[\alpha]_{20}^D - 89.7$  ( $c = 0.35$ , MeOH); UV  $\lambda_{\text{MeOH}}$  nm ( $\log \epsilon$ ): 212 (4.39), 234 (4.31), 240 (4.26), 330 (4.27), 345 (4.31), 362 (4.14); IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>): 3345, 1641, 1618, 1598, 1554, 1502, 1468, 1329, 1268, 849, 788, 767; <sup>1</sup>H and <sup>13</sup>C NMR spectral data (Tables 1 and 2); EI-MS  $m/z$  333 [M]<sup>+</sup> (7.2), 315 [M–H<sub>2</sub>O]<sup>+</sup> (9.3), 304 (21.1), 301 (22.3), 285 (26.8), 272 (100); HR-ESI-MS  $m/z$  334.1184 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>, 334.1186).

### 3.3.2 (7R,8S)-7-Hydroxy-8-ethoxy-rutaecarpine (**2**)

A white amorphous powder;  $[\alpha]_{20}^D - 52.8$  ( $c = 0.14$ , MeOH); UV  $\lambda_{\text{MeOH}}$  nm ( $\log \epsilon$ ): 214 (4.35), 232 (4.25), 240 (4.22), 331 (4.25), 346 (4.32), 362 (4.15); IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>): 3271, 1643, 1622, 1597, 1466, 1329, 1220, 1196, 1057, 736; <sup>1</sup>H and <sup>13</sup>C NMR spectral data (Tables 1 and 2); EI-MS  $m/z$  347 [M]<sup>+</sup> (4.8), 318 [M–CH<sub>3</sub>CH<sub>2</sub>]<sup>+</sup> (24.1), 301 [M–CH<sub>3</sub>CH<sub>2</sub>OH]<sup>+</sup> (17.8), 285 (15.0), 272 (100); HR-ESI-MS  $m/z$  348.1342 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>, 348.1343).

## 3.4 Determination of cytotoxic activities

Human promyelocytic leukemia cell line HL-60 and human gastric carcinoma cell line N-87 were used. Both cells were

cultured in RPMI-1640 medium (GIBCO, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (GIBCO) in 5% CO<sub>2</sub> at 37°C. The MTT method [19] was used to assay cytotoxicity in 96-well microplates. Briefly, 90  $\mu$ l of the cell suspension was seeded into each well with an initial density of  $5 \times 10^4$  cells/ml (HL-60) and  $2 \times 10^5$  cells/ml (N-87), respectively. Each tumor cell line was cultured for 24 h before being exposed to each test compound at concentrations of 0.1, 1, 10, 20, and 40  $\mu$ M in triplicate for 48 h, with Vincristine (VCR) used as a positive control. The absorbance was detected by a Microplate Reader at 490 nm, and IC<sub>50</sub> values were calculated by the software origin 7.5.

## Acknowledgements

This research was supported by the National Key Technology R&D Program of China (2011BAI07B08).

## References

- [1] Chinese Pharmacopoeia Commission, *Pharmacopoeia of the People's Republic of China* (China Medical Science and Technology Press, Beijing, 2010), Vol. I, p. 160.
- [2] M.Y. Zhao and X.W. Yang, *Chromatographia* **67**, 543 (2008).
- [3] X.W. Yang, H. Zhang, M. Li, L.J. Du, Z. Yang, and S.Y. Xiao, *J. Asian Nat. Prod. Res.* **8**, 697 (2006).
- [4] M. Ogasawara, T. Matsubara, and H. Suzuki, *Biol. Pharm. Bull.* **24**, 720 (2001).
- [5] M. Ogasawara, T. Matsubara, and H. Suzuki, *Biol. Pharm. Bull.* **24**, 917 (2001).
- [6] S.F. Kan, C.H. Yu, H.F. Pu, J.M. Hsu, M.J. Chen, and P.S. Wang, *J. Cell. Biochem.* **101**, 44 (2007).
- [7] J. Teng and X.W. Yang, *Heterocycles* **68**, 1691 (2006).
- [8] X.W. Yang, J. Teng, W. Xu, X.J. Tian, and Y. Wang, *Phytother. Res.* **23**, 56 (2009).
- [9] X.W. Yang and J. Teng, *J. Chin. Pharm. Sci.* **16**, 20 (2007).
- [10] J. Teng and X.W. Yang, *Pharmazie* **61**, 1038 (2006).

- [11] M.Y. Zhao and X.W. Yang, *J. Asian Nat. Prod. Res.* **10**, 759 (2008).
- [12] W.S. Sheen, I.L. Tsai, C.M. Teng, F.N. Ko, and I.S. Chen, *Planta Med.* **62**, 175 (1996).
- [13] K.M. Ng, A.I. Gray, and P.G. Waterman, *J. Nat. Prod.* **50**, 1160 (1987).
- [14] A. Ikuta, H. Urabe, and T. Nakamura, *J. Nat. Prod.* **61**, 1012 (1998).
- [15] H. Zhang, X.W. Yang, and Y.X. Cui, *Chin. J. Magn. Resonance* **16**, 563 (1999).
- [16] X.W. Yang, H. Zhang, and J. Hu, *J. Trop. Subtrop. Bot.* **16**, 244 (2008).
- [17] T.S. Wu, J.H. Yeh, P.L. Wu, K.T. Chen, L.C. Lin, and C.F. Chen, *Heterocycles* **41**, 1071 (1995).
- [18] L. Huang and D.Q. Yu, *Application of Ultraviolet Spectrum in Organic Chemistry, Part II* (Science Press, Beijing, 1998), pp. 132–137.
- [19] T.J. Mosumann, *J. Immunol. Methods* **65**, 55 (1983).